Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXASNASDAQ:GHNASDAQ:NTRANASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXASExact Sciences$53.40+3.4%$45.64$39.97▼$72.83$10.07B0.922.59 million shs1.77 million shsGHGuardant Health$41.66-0.1%$43.70$20.14▼$52.92$5.16B1.492.21 million shs2.23 million shsNTRANatera$157.29+3.5%$147.70$92.14▼$183.00$21.26B1.791.38 million shs1.94 million shsVCYTVeracyte$30.76+3.5%$31.00$19.73▼$47.32$2.33B2.14882,049 shs1.08 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXASExact Sciences+3.25%+0.13%+20.13%+4.58%-0.21%GHGuardant Health-0.14%-5.43%-4.69%-4.45%+86.23%NTRANatera+4.17%-0.06%+6.25%-7.32%+49.39%VCYTVeracyte+4.73%-1.79%-3.27%-24.92%+43.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEXASExact Sciences4.6201 of 5 stars4.52.00.04.73.51.70.6GHGuardant Health4.8619 of 5 stars4.54.00.04.34.02.50.6NTRANatera2.8934 of 5 stars3.53.00.00.02.92.50.6VCYTVeracyte3.8974 of 5 stars4.41.00.04.32.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXASExact Sciences 2.95Moderate Buy$70.9032.77% UpsideGHGuardant Health 3.05Buy$52.3225.58% UpsideNTRANatera 3.00Buy$181.8215.60% UpsideVCYTVeracyte 2.70Moderate Buy$40.9032.96% UpsideCurrent Analyst Ratings BreakdownLatest NTRA, GH, VCYT, and EXAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/6/2025GHGuardant HealthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.005/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/5/2025GHGuardant HealthScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $57.005/2/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$55.00 ➝ $75.005/2/2025EXASExact SciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$52.00 ➝ $54.005/2/2025EXASExact SciencesEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $66.005/2/2025EXASExact SciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$69.00 ➝ $72.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXASExact Sciences$2.83B3.56$6.08 per share8.79$12.93 per share4.13GHGuardant Health$774.00M6.67N/AN/A$1.34 per share31.09NTRANatera$1.83B11.61N/AN/A$6.37 per share24.69VCYTVeracyte$463.39M5.20$0.07 per share442.29$14.30 per share2.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXASExact Sciences-$204.15M-$5.51N/A106.80N/A-37.29%-5.29%-2.45%7/30/2025 (Estimated)GHGuardant Health-$479.45M-$3.39N/AN/AN/A-59.05%-19,157.20%-25.96%N/ANTRANatera-$434.80M-$1.47N/AN/AN/A-14.01%-26.23%-14.27%N/AVCYTVeracyte-$74.40M$0.41N/A42.72N/A-2.18%3.02%2.80%N/ALatest NTRA, GH, VCYT, and EXAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million5/1/2025Q1 2025EXASExact Sciences-$0.37-$0.21+$0.16-$0.54$688.58 million$706.79 million4/30/2025Q1 2025GHGuardant Health-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million2/27/2025Q4 2024NTRANatera-$0.42-$0.41+$0.01-$0.41$447.91 million$476.10 million2/24/2025Q4 2024VCYTVeracyte$0.29$0.36+$0.07$0.06$110.73 million$118.63 million2/20/2025Q4 2024GHGuardant Health-$0.75-$0.90-$0.15-$0.90$192.50 million$201.81 million2/19/2025Q4 2024EXASExact Sciences-$0.29-$0.06+$0.23-$4.67$701.45 million$713.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXASExact SciencesN/AN/AN/AN/AN/AGHGuardant HealthN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXASExact Sciences0.972.151.93GHGuardant HealthN/A6.225.85NTRANatera0.334.394.23VCYTVeracyteN/A5.084.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXASExact Sciences88.82%GHGuardant Health92.60%NTRANatera99.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipEXASExact Sciences1.36%GHGuardant Health5.50%NTRANatera7.60%VCYTVeracyte1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXASExact Sciences6,400188.64 million182.56 millionOptionableGHGuardant Health1,790123.89 million116.76 millionNot OptionableNTRANatera3,020135.19 million121.99 millionOptionableVCYTVeracyte79078.31 million76.49 millionOptionableNTRA, GH, VCYT, and EXAS HeadlinesRecent News About These CompaniesGranahan Investment Management LLC Has $1.96 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 13 at 7:14 AM | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Acquired by Fred Alger Management LLCMay 13 at 6:03 AM | marketbeat.comAxa S.A. Trims Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 11 at 4:49 AM | marketbeat.comNorthern Trust Corp Has $42.34 Million Stock Position in Veracyte, Inc. (NASDAQ:VCYT)May 11 at 4:33 AM | marketbeat.comNeedham & Company LLC Cuts Veracyte (NASDAQ:VCYT) Price Target to $41.00May 11 at 3:27 AM | americanbankingnews.comVeracyte (NASDAQ:VCYT) Stock Price Down 5.8% Following Analyst DowngradeMay 11 at 1:55 AM | americanbankingnews.comBreaking Down Veracyte: 7 Analysts Share Their ViewsMay 10 at 7:33 PM | nasdaq.comVeracyte, Inc. Just Recorded A 260% EPS Beat: Here's What Analysts Are Forecasting NextMay 10 at 2:33 PM | finance.yahoo.comVeracyte (NASDAQ:VCYT) Price Target Cut to $41.00 by Analysts at Needham & Company LLCMay 10 at 8:06 AM | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Bought by Driehaus Capital Management LLCMay 10 at 7:17 AM | marketbeat.comCaption Management LLC Invests $376,000 in Veracyte, Inc. (NASDAQ:VCYT)May 10 at 5:57 AM | marketbeat.comTudor Investment Corp ET AL Sells 20,531 Shares of Veracyte, Inc. (NASDAQ:VCYT)May 10 at 4:11 AM | marketbeat.comVeracyte (NASDAQ:VCYT) Given New $42.00 Price Target at UBS GroupMay 10 at 1:47 AM | americanbankingnews.comVeracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin UpMay 9, 2025 | zacks.comBridgeway Capital Management LLC Decreases Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 9, 2025 | marketbeat.comAQR Capital Management LLC Grows Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 9, 2025 | marketbeat.comWhat Makes Veracyte (VCYT) a New Buy StockMay 8, 2025 | zacks.com4VCYT : Breaking Down Veracyte: 7 Analysts Share Their ViewsMay 8, 2025 | benzinga.comCasdin Capital LLC Decreases Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)May 8, 2025 | marketbeat.comVeracyte Inc (VCYT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ExpansionsMay 8, 2025 | finance.yahoo.comBosun Asset Management LLC Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT)May 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Joby Aviation Shares Eye Breakout After Transition Flight WinBy Jeffrey Neal Johnson | April 30, 2025View Joby Aviation Shares Eye Breakout After Transition Flight WinRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsBy Ryan Hasson | May 5, 2025View Rocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsTesla Stock Eyes Breakout With Earnings on DeckBy Sam Quirke | April 16, 2025View Tesla Stock Eyes Breakout With Earnings on Deck5 Stocks That Crushed Earnings and Guidance ForecastsBy Thomas Hughes | May 8, 2025View 5 Stocks That Crushed Earnings and Guidance ForecastsNTRA, GH, VCYT, and EXAS Company DescriptionsExact Sciences NASDAQ:EXAS$53.40 +1.77 (+3.43%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$53.48 +0.08 (+0.14%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Guardant Health NASDAQ:GH$41.66 -0.06 (-0.14%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$42.00 +0.34 (+0.82%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Natera NASDAQ:NTRA$157.29 +5.34 (+3.51%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$156.10 -1.19 (-0.76%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Veracyte NASDAQ:VCYT$30.76 +1.05 (+3.53%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$30.33 -0.43 (-1.40%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
